Europe Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Type (Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs), By Distribution Channel, By Age, By Country and Growth Forecast, 2024 - 2031
The Europe Huntington’s Disease Treatment Market would witness market growth of 8.8% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Huntington’s Disease Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $51,954.4 Thousands by 2031. The UK market is exhibiting a CAGR of 7.9% during (2024 - 2031). Additionally, The France market would experience a CAGR of 9.7% during (2024 - 2031).
Disease-modifying therapies aim to alter the course of Huntington’s Disease by targeting the underlying genetic and biological mechanisms driving neurodegeneration. The goal of antisense oligonucleotide (ASO) and RNA interference (RNAi) therapy is to decrease the generation of mutant huntingtin protein (mHTT), which is neurotoxic. These therapies slow disease progression by lowering mHTT levels in the brain. Also, CRISPR/Cas9 and other gene editing approaches can potentially edit the mutant HTT gene directly, correcting the genetic mutation responsible for HD or modifying its expression.
Supportive care strategies are integral to managing the complex needs of HD patients and addressing the disease’s broader impact on their lives. HD patients benefit from care provided by multidisciplinary teams, including neurologists, genetic counselors, psychiatrists, physical therapists, occupational therapists, and social workers. This comprehensive approach addresses HD’s diverse medical, psychological, and social aspects.
The UK develops specialized healthcare services and infrastructure to meet the needs of individuals with HD. This includes HD clinics staffed by multidisciplinary teams of neurologists, genetic counselors, psychologists, and social workers. These clinics provide comprehensive care and support tailored to the complex needs of HD patients and their families. As per Brain Research UK, around 7,000 people are living with Huntington’s disease (HD) in the UK. In conclusion, the prevalence of Huntington’s disease in the region is driving the market's growth.
Based on Drug Type, the market is segmented into Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies, and Online Pharmacies. Based on Age, the market is segmented into Below 50 years and Above 50 years. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- Hikma Pharmaceuticals PLC
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Neurocrine Biosciences Inc.
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd.
By Drug Type
- Approved Drugs
- Tetrabenazine
- Deutetrabenazine
- Offlabel Drugs
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Pharmacies
- Below 50 years
- Above 50 years
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Huntington’s Disease Treatment Market, by Drug Type
- 1.4.2 Europe Huntington’s Disease Treatment Market, by Distribution Channel
- 1.4.3 Europe Huntington’s Disease Treatment Market, by Age
- 1.4.4 Europe Huntington’s Disease Treatment Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
- 3.3 Porter Five Forces Analysis
- Chapter 4. Europe Huntington’s Disease Treatment Market by Drug Type
- 4.1 Europe Approved Drugs Market by Country
- 4.2 Europe Huntington’s Disease Treatment Market by Approved Drugs Type
- 4.2.1 Europe Tetrabenazine Market by Country
- 4.2.2 Europe Deutetrabenazine Market by Country
- 4.3 Europe Offlabel Drugs Market by Country
- Chapter 5. Europe Huntington’s Disease Treatment Market by Distribution Channel
- 5.1 Europe Hospital Pharmacies Market by Country
- 5.2 Europe Drug Store & Retail Pharmacies Market by Country
- 5.3 Europe Online Pharmacies Market by Country
- Chapter 6. Europe Huntington’s Disease Treatment Market by Age
- 6.1 Europe Below 50 years Market by Country
- 6.2 Europe Above 50 years Market by Country
- Chapter 7. Europe Huntington’s Disease Treatment Market by Country
- 7.1 Germany Huntington’s Disease Treatment Market
- 7.1.1 Germany Huntington’s Disease Treatment Market by Drug Type
- 7.1.1.1 Germany Huntington’s Disease Treatment Market by Approved Drugs Type
- 7.1.2 Germany Huntington’s Disease Treatment Market by Distribution Channel
- 7.1.3 Germany Huntington’s Disease Treatment Market by Age
- 7.2 UK Huntington’s Disease Treatment Market
- 7.2.1 UK Huntington’s Disease Treatment Market by Drug Type
- 7.2.1.1 UK Huntington’s Disease Treatment Market by Approved Drugs Type
- 7.2.2 UK Huntington’s Disease Treatment Market by Distribution Channel
- 7.2.3 UK Huntington’s Disease Treatment Market by Age
- 7.3 France Huntington’s Disease Treatment Market
- 7.3.1 France Huntington’s Disease Treatment Market by Drug Type
- 7.3.1.1 France Huntington’s Disease Treatment Market by Approved Drugs Type
- 7.3.2 France Huntington’s Disease Treatment Market by Distribution Channel
- 7.3.3 France Huntington’s Disease Treatment Market by Age
- 7.4 Russia Huntington’s Disease Treatment Market
- 7.4.1 Russia Huntington’s Disease Treatment Market by Drug Type
- 7.4.1.1 Russia Huntington’s Disease Treatment Market by Approved Drugs Type
- 7.4.2 Russia Huntington’s Disease Treatment Market by Distribution Channel
- 7.4.3 Russia Huntington’s Disease Treatment Market by Age
- 7.5 Spain Huntington’s Disease Treatment Market
- 7.5.1 Spain Huntington’s Disease Treatment Market by Drug Type
- 7.5.1.1 Spain Huntington’s Disease Treatment Market by Approved Drugs Type
- 7.5.2 Spain Huntington’s Disease Treatment Market by Distribution Channel
- 7.5.3 Spain Huntington’s Disease Treatment Market by Age
- 7.6 Italy Huntington’s Disease Treatment Market
- 7.6.1 Italy Huntington’s Disease Treatment Market by Drug Type
- 7.6.1.1 Italy Huntington’s Disease Treatment Market by Approved Drugs Type
- 7.6.2 Italy Huntington’s Disease Treatment Market by Distribution Channel
- 7.6.3 Italy Huntington’s Disease Treatment Market by Age
- 7.7 Rest of Europe Huntington’s Disease Treatment Market
- 7.7.1 Rest of Europe Huntington’s Disease Treatment Market by Drug Type
- 7.7.1.1 Rest of Europe Huntington’s Disease Treatment Market by Approved Drugs Type
- 7.7.2 Rest of Europe Huntington’s Disease Treatment Market by Distribution Channel
- 7.7.3 Rest of Europe Huntington’s Disease Treatment Market by Age
- Chapter 8. Company Profiles
- 8.1 Dr. Reddy’s Laboratories Ltd.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Segmental and Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 SWOT Analysis
- 8.2 Takeda Pharmaceutical Company Limited
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expense
- 8.2.5 SWOT Analysis
- 8.3 Sun Pharmaceutical Industries Ltd.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expenses
- 8.3.5 SWOT Analysis
- 8.4 Hikma Pharmaceuticals PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Segmental and Regional Analysis
- 8.4.4 Research & Development Expenses
- 8.5 Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- 8.5.1 Company Overview
- 8.6 Teva Pharmaceutical Industries Ltd.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Regional Analysis
- 8.6.4 Research & Development Expenses
- 8.6.5 SWOT Analysis
- 8.7 Bausch Health Companies, Inc
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental and Regional Analysis
- 8.7.4 Research & Development Expense
- 8.7.5 SWOT Analysis
- 8.8 Neurocrine Biosciences Inc.
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Research & Development Expenses
- 8.9 Pfizer, Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Regional & Segmental Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 SWOT Analysis
- 8.10. F. Hoffmann-La Roche Ltd.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Segmental and Regional Analysis
- 8.10.4 Research & Development Expense
- 8.10.5 SWOT Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook